top of page
OUR COMPANY
OUR MISSION
OUR LEADERSHIP
PIPELINE
CTB-1
CTD-1
NEWS
CONTACT
More
Use tab to navigate through the menu items.
News
All Posts
Search
Advancing Cancer Immunotherapy: CTD-1
May 6, 2024
GTS Biotech Receives Rare Pediatric Disease Designation from the FDA for CTB-1
Apr 9, 2024
FDA Grants Orphan Drug Designation to GTS Biotech’s CTB-1 as a Treatment for Osteosarcoma
Mar 26, 2024
Cinnamtannin B-1 Inhibits the Progression of Osteosarcoma
Jan 24, 2024
Autoimmune activity of CTD-1
Aug 2, 2023
Press Release: CTB-1 is now under FDA review!
Aug 2, 2023
bottom of page
%20(1)_edited.png)
